(HUN) Huntsman - Overview
Stock: Polyurethanes, Amines, Epoxy, Maleic Anhydride
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 6.97% |
| Yield on Cost 5y | 3.52% |
| Yield CAGR 5y | 3.69% |
| Payout Consistency | 96.2% |
| Payout Ratio | 180.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 48.6% |
| Relative Tail Risk | -6.57% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.13 |
| Alpha | -32.28 |
| Character TTM | |
|---|---|
| Beta | 1.424 |
| Beta Downside | 1.169 |
| Drawdowns 3y | |
|---|---|
| Max DD | 72.71% |
| CAGR/Max DD | -0.28 |
Description: HUN Huntsman January 16, 2026
Huntsman Corporation (NYSE:HUN) is a global diversified chemicals producer organized into three business segments: Polyurethanes, Performance Products, and Advanced Materials. The Polyurethanes segment supplies core raw materials such as methyl diphenyl diisocyanate, polyols, and thermoplastic polyurethane, along with aromatic co-products. Performance Products focuses on specialty amines, catalysts, and maleic anhydrides, while Advanced Materials delivers epoxy, phenoxy, acrylic, and other high-performance polymer formulations, including carbon nanomaterials.
The company’s end-markets span automotive, construction, aerospace, electronics, packaging, and oil & gas, with sales channeled through a network of distributors and agents. Technical service support is offered both pre- and post-sale, reinforcing customer lock-in across a broad product portfolio.
Key recent metrics: FY 2023 revenue of roughly $9.5 billion, adjusted EBITDA margin of 12 %, and free cash flow of $620 million. The business is highly sensitive to macro-driven demand for polyurethanes in automotive lightweighting and construction-related insulation, sectors that have shown a 4-5 % annual growth rate in the United States over the past three years. Additionally, Huntsman’s acquisition of Ineos Styrolution’s polyurethanes assets in 2022 added ~15 % incremental capacity, improving its scale advantage.
For a deeper dive into HUN’s valuation metrics and scenario analysis, you may find ValueRay’s research platform useful.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -329.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 2.02 > 1.0 |
| NWC/Revenue: 10.05% < 20% (prev 12.24%; Δ -2.19% < -1%) |
| CFO/TA 0.05 > 3% & CFO 366.0m > Net Income -329.0m |
| Net Debt (1.93b) to EBITDA (168.0m): 11.51 < 3 |
| Current Ratio: 1.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (173.0m) vs 12m ago 0.52% < -2% |
| Gross Margin: 13.41% > 18% (prev 0.14%; Δ 1327 % > 0.5%) |
| Asset Turnover: 80.19% > 50% (prev 81.63%; Δ -1.44% > 0%) |
| Interest Coverage Ratio: -1.53 > 6 (EBITDA TTM 168.0m / Interest Expense TTM 79.0m) |
Altman Z'' 1.51
| A: 0.08 (Total Current Assets 2.18b - Total Current Liabilities 1.60b) / Total Assets 7.08b |
| B: 0.27 (Retained Earnings 1.92b / Total Assets 7.08b) |
| C: -0.02 (EBIT TTM -121.0m / Avg Total Assets 7.21b) |
| D: 0.20 (Book Value of Equity 796.0m / Total Liabilities 4.08b) |
| Altman-Z'' Score: 1.51 = BB |
Beneish M -3.13
| DSRI: 0.96 (Receivables 768.0m/829.0m, Revenue 5.78b/5.99b) |
| GMI: 1.03 (GM 13.41% / 13.86%) |
| AQI: 1.04 (AQ_t 0.29 / AQ_t-1 0.28) |
| SGI: 0.97 (Revenue 5.78b / 5.99b) |
| TATA: -0.10 (NI -329.0m - CFO 366.0m) / TA 7.08b) |
| Beneish M-Score: -3.13 (Cap -4..+1) = AA |
What is the price of HUN shares?
Over the past week, the price has changed by +24.40%, over one month by +23.15%, over three months by +82.91% and over the past year by -16.45%.
Is HUN a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 12
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the HUN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.8 | -19.7% |
| Analysts Target Price | 10.8 | -19.7% |
| ValueRay Target Price | 14 | 4.3% |
HUN Fundamental Data Overview February 03, 2026
P/S = 0.3253
P/B = 0.7023
P/EG = 1.79
Revenue TTM = 5.78b USD
EBIT TTM = -121.0m USD
EBITDA TTM = 168.0m USD
Long Term Debt = 1.63b USD (from longTermDebt, last quarter)
Short Term Debt = 435.0m USD (from shortTermDebt, last quarter)
Debt = 2.40b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.93b USD (from netDebt column, last quarter)
Enterprise Value = 3.81b USD (1.88b + Debt 2.40b - CCE 468.0m)
Interest Coverage Ratio = -1.53 (Ebit TTM -121.0m / Interest Expense TTM 79.0m)
EV/FCF = 19.16x (Enterprise Value 3.81b / FCF TTM 199.0m)
FCF Yield = 5.22% (FCF TTM 199.0m / Enterprise Value 3.81b)
FCF Margin = 3.44% (FCF TTM 199.0m / Revenue TTM 5.78b)
Net Margin = -5.69% (Net Income TTM -329.0m / Revenue TTM 5.78b)
Gross Margin = 13.41% ((Revenue TTM 5.78b - Cost of Revenue TTM 5.00b) / Revenue TTM)
Gross Margin QoQ = 13.97% (prev 12.48%)
Tobins Q-Ratio = 0.54 (Enterprise Value 3.81b / Total Assets 7.08b)
Interest Expense / Debt = 0.83% (Interest Expense 20.0m / Debt 2.40b)
Taxrate = 21.0% (US default 21%)
NOPAT = -95.6m (EBIT -121.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.36 (Total Current Assets 2.18b / Total Current Liabilities 1.60b)
Debt / Equity = 0.87 (Debt 2.40b / totalStockholderEquity, last quarter 2.77b)
Debt / EBITDA = 11.51 (Net Debt 1.93b / EBITDA 168.0m)
Debt / FCF = 9.71 (Net Debt 1.93b / FCF TTM 199.0m)
Total Stockholder Equity = 2.88b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.56% (Net Income -329.0m / Total Assets 7.08b)
RoE = -11.44% (Net Income TTM -329.0m / Total Stockholder Equity 2.88b)
RoCE = -2.69% (EBIT -121.0m / Capital Employed (Equity 2.88b + L.T.Debt 1.63b))
RoIC = -1.98% (negative operating profit) (NOPAT -95.6m / Invested Capital 4.83b)
WACC = 5.27% (E(1.88b)/V(4.28b) * Re(11.16%) + D(2.40b)/V(4.28b) * Rd(0.83%) * (1-Tc(0.21)))
Discount Rate = 11.16% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.29%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈142.6m ; Y1≈93.6m ; Y5≈42.7m
Fair Price DCF = N/A (negative equity: EV 1.36b - Net Debt 1.93b = -572.1m; debt exceeds intrinsic value)
EPS Correlation: -77.17 | EPS CAGR: -19.60% | SUE: 1.14 | # QB: 1
Revenue Correlation: -85.35 | Revenue CAGR: -11.49% | SUE: 0.53 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.14 | Chg30d=-0.000 | Revisions Net=-4 | Analysts=9
EPS next Year (2026-12-31): EPS=-0.33 | Chg30d=-0.010 | Revisions Net=-1 | Growth EPS=+50.5% | Growth Revenue=+3.3%